Mauskopf, Josephine A.; Richter, Anke; Annemans, Lieven; … - In: PharmacoEconomics 18 (2000) 3, pp. 239-251
and cost consequences in this setting. Objective: To compare the cost effectiveness of different CMV management strategies … cost per patient was from Lstg 157 to Lstg 438 higher with oral valaciclovir prophylaxis compared with intravenous … ganciclovir prophylaxis and the incremental cost per case of CMV disease avoided with valaciclovir prophylaxis ranged from Lstg …